প্রকাশ: 26/01/2022
Pfizer Inc and BioNTech SE said on Tuesday they started a
clinical trial to test a new version of their vaccine specifically designed to
target the Covid-19 Omicron variant, which has eluded some of the protection
provided by the original two-dose vaccine regimen.
Banking on volunteers in the United States, the companies
plan to test the immune response generated by the Omicron-based vaccine both as
a three-shot regimen in unvaccinated people and as a booster shot for people
who already received two doses of their original vaccine.
They are also testing a fourth dose of the current vaccine
against a fourth dose of the Omicron-based vaccine in people who received a
third dose of the Pfizer/BioNTech vaccine three to six months earlier.
The companies plan to study the safety and tolerability of
the shots in the more than 1,400 people who will be enrolled in the trial.
"While current research and real-world data show that
boosters continue to provide a high level of protection against severe disease
and hospitalization with Omicron, we recognize the need to be prepared in the
event this protection wanes over time and to potentially help address Omicron
and new variants in the future," Pfizer's head of vaccine research and
development, Kathrin Jansen, said in a statement.
Depending on the amount of clinical trial data required by
regulators, it may not be possible to realize a current plan to launch an
Omicron-targeting vaccine by the end of March, BioNTech said.
Pfizer has said that two doses of the original vaccine may
not be sufficient to protect against infection from Omicron, and that
protection against hospitalizations and deaths may be waning.
Still, the US Centers for Disease Control and Prevention
says a third dose of an mRNA vaccine like the Pfizer/BioNTech vaccine has
provided 90% protection against hospitalization due to Covid-19.
Some countries have already started offering additional
booster doses, but a recent study from Israel showed that while a fourth dose
of an mRNA vaccine boosted antibodies, the level was not high enough to prevent
Omicron infection.
DATA The European Medicines Agency (EMA) said on Friday that
international regulators want data from clinical studies like the one being
done by Pfizer and BioNTech before approval of a new vaccine.
EMA said these studies should show that the new vaccines
elicit more neutralising antibodies in the blood than current vaccines and
might also protect against new variants of concern.
BioNTech declined to comment on what type of data it was
asked to file with regulators.
It said an analysis of antibodies elicited by its
Omicron-targeted booster should help answer whether shots will be needed that
address more than one variant at a time. It hopes to show the antibodies
neutralise a spectrum of variants.
Still, some scientists question whether any change is
currently needed.
"The goal of this vaccine is to protect against serious
illness," said Dr. Paul Offit, an infectious disease expert at the
University of Pennsylvania. "To date, these vaccines do that, including
protection against Omicron."
প্রধান সম্পাদকঃ সৈয়দ বোরহান কবীর
ক্রিয়েটিভ মিডিয়া লিমিটেডের অঙ্গ প্রতিষ্ঠান
বার্তা এবং বাণিজ্যিক কার্যালয়ঃ ২/৩ , ব্লক - ডি , লালমাটিয়া , ঢাকা -১২০৭
নিবন্ধিত ঠিকানাঃ বাড়ি# ৪৩ (লেভেল-৫) , রোড#১৬ নতুন (পুরাতন ২৭) , ধানমন্ডি , ঢাকা- ১২০৯
ফোনঃ +৮৮-০২৯১২৩৬৭৭